Minerva Neurosciences Inc (NASDAQ:NERV) traded today at a new 52-week low of $1.95. So far today approximately 173,000 shares have been exchanged, as compared to an average 30-day volume of 662,000 shares.
Minerva Neurosciences Inc share prices have moved between a 52-week high of $4.12 and the current low of $1.95 and are currently at $2.01 per share.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and
commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include
schizophrenia, insomnia, major depressive disorder and Parkinson’s disease. Its product portfolio and potential indications include Roluperidone
for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive
disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson’s disease.
Minerva Neurosciences Inc (NASDAQ:NERV) is currently priced 60.7% above its average consensus analyst price target of $0.79.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer